Novartis’ new treatment for heart failure has been granted Breakthrough Therapy designation status by the FDA. RLX030 (serelaxin) is for …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

